APA (7th ed.) Citation

Retlich, S., Duval, V., Ring, A., Staab, A., Hüttner, S., Jungnik, A., . . . Graefe-Mody, U. (2010). Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5mg–10mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects. Clinical pharmacokinetics, 49(12), 829-840. https://doi.org/10.2165/11536620-000000000-00000

Chicago Style (17th ed.) Citation

Retlich, Silke, Vincent Duval, Arne Ring, Alexander Staab, Silke Hüttner, Arvid Jungnik, Ulrich Jaehde, Klaus A. Dugi, and Ulrike Graefe-Mody. "Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5mg–10mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects." Clinical Pharmacokinetics 49, no. 12 (2010): 829-840. https://doi.org/10.2165/11536620-000000000-00000.

MLA (9th ed.) Citation

Retlich, Silke, et al. "Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5mg–10mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects." Clinical Pharmacokinetics, vol. 49, no. 12, 2010, pp. 829-840, https://doi.org/10.2165/11536620-000000000-00000.